(2023)
Pretransplant Functional Status Predicts Postoperative Morbidity and Mortality after Liver Transplantation in Patients with Cirrhosis.
GUT AND LIVER.
17,
5
(2023)
Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma.
JHEP REPORTS.
5,
9
(2023)
Validation of non-invasive diagnosis of CSPH in patients with compensated advanced chronic liver disease according to Baveno VII.
LIVER INTERNATIONAL.
43,
9
(2023)
Transgenic viral expression of PH-20, IL-12, and sPD1-Fc enhances immune cell infiltration and anti-tumor efficacy of an oncolytic virus.
MOLECULAR THERAPY-ONCOLYTICS.
30,
9
(2023)
Clinical Outcomes and Validation of Ursodeoxycholic Acid Response Scores in Patients with Korean Primary Biliary Cholangitis: A Multicenter Cohort Study.
GUT AND LIVER.
17,
4
(2023)
Improved on-treatment fibrosis-4 during antiviral therapy and lower hepatocellular carcinoma risk in cirrhotic patients with hepatitis B.
SCIENTIFIC REPORTS.
13,
1
(2023)
Causal effect of adiposity on the risk of 19 gastrointestinal diseases: a Mendelian randomization study.
OBESITY.
31,
5
(2022)
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study.
LIVER CANCER.
11,
6
(2022)
Changes in the prevalence of hepatitis B and metabolic abnormalities among young men in Korea.
KOREAN JOURNAL OF INTERNAL MEDICINE.
37,
5
(2022)
Clinical Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma Patients with Undetectable Serum HBV DNA Levels.
DIGESTIVE DISEASES AND SCIENCES.
67,
9
(2022)
Increased risk of pancreatic cancer in individuals with non-alcoholic fatty liver disease.
SCIENTIFIC REPORTS.
12,
1
(2022)
Safety and Efficacy of Liver-Directed Radiotherapy in Combination With Lenvatinib for Hepatocelluar Carcinoma With Macroscopic Tumor Thrombosis.
FRONTIERS IN ONCOLOGY.
12,
-
(2022)
Prognostic significance of cachexia index in patients with advanced hepatocellular carcinoma treated with systemic chemotherapy.
SCIENTIFIC REPORTS.
12,
1
(2022)
KASL clinical practice guidelines for management of chronic hepatitis B.
CLINICAL AND MOLECULAR HEPATOLOGY.
28,
2
(2022)
Expert consensus on the management of adverse events in patients receiving lenvatinib for hepatocellular carcinoma.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY.
37,
3
(2022)
Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial.
GENOME MEDICINE.
14,
1
(2022)
Age and fibrosis index for the prediction of hepatocellular carcinoma risk in patients with high hepatitis B virus DNA but normal alanine aminotransferase.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY.
34,
1
(2022)
Incidence and risk factors for development of hepatocellular carcinoma at young age in patients with chronic hepatitis B.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY.
57,
1
(2021)
Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib.
ESMO Open.
6,
6
(2021)
Proton Pump Inhibitor Use Increases Pyogenic Liver Abscess Risk: A Nationwide Cohort Study.
JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY.
27,
4
학술회의논문
(2020)
Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World Practice in Korea.
KDDW2020.
대한민국
(2020)
NOX4 knockdown promotes tumorigenesis arising from fibrotic background liver by inducing M2-macrophages in tumor microenvironment.
대한간학회, 춘/추계 학술대회.
대한민국
(2019)
CD47 BLOCKADE SYNERGIZES WITH PD-1 CHECKPOINT INHIBITOR AND ENHANCES ANTI-TUMOR EFFICACY IN HEPATOCELLULAR CARCINOMA.
AASLD 2019.
미국
(2019)
LOW INCIDENCE OF HEPATITIS B REACTIVATION AFTER KIDNEY TRANSPLANTATION IN HEPATITIS B SURFACE ANTIGEN-NEGATIVE AND CORE ANTIBODY-POSITIVE RECIPIENTS.
AASLD2019.
미국
(2019)
SUBSTANTIAL RISK OF HEPATOCELLULAR CARCINOMA RECURRENCE EVEN AFTER FIVE YEARS OF NO-RECURRENCE PERIOD AMONG EARLY STAGE HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH RESECTION OR RADIOFREQUENCY ABLATION.
AASLD 2019.
미국
(2019)
CD47 blockade synergizes with PD-1 checkpoint inhibitor and enhances anti-tumor efficacy in syngeneic preclinical model of hepatocellular carcinoma.
APPLE 2019.
일본
(2019)
Antiviral Treatment Status at Hepatocellular Carcinoma Development Affects Overall Survival in Chronic Hepatitis B Patients.
The Liver Week 2019.
대한민국
(2019)
Extremely Low Risk of Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients with Immune Tolerant Phase: A Multicenter Retrospective Cohort Study.
The Liver Week 2019.
대한민국
(2019)
Prognostic Value of Alpha-Fetoprotein in Patients Who Achieved Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma.
The Liver Week 2019.
대한민국
(2019)
Risk of Hepatocellular Carcinoma in Patients with Immune- Tolerant Chronic Hepatitis B.
The Liver Week 2019.
대한민국
(2019)
Statin Use and the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B.
The Liver Week 2019.
대한민국
(2018)
EP-0099 (PE-0402) Targeting CD47 enhances the
efficacy of anti-PD-1 immune checkpoint
inhibition in syngeneic preclinical model of HCC.
아시아태평양소화기학회(APDW).
대한민국
(2018)
Disruption of CD47-SIRPa Axis as a Novel Potent Immunotherapy in Hepatocellular Carcinoma.
아시아태평양간암학회(APPLE).
대한민국
(2018)
Radiation therapy potentiates the efficacy of immune checkpoint blockade in a
syngeneic murine hepatocellular carcinoma model.
EACR conference.
영국
(2017)
Clinical Characteristics, Potencial Etiology and Mode of Detection for Non-B Non-C Hepatocellular Carcinoma in Korea.
KDDW 2017.
대한민국
(2017)
Comparison of Treatment Efficacy between Entecavir (ETV) and Tenofovir Disoproxil Fumarate (TDF) in Treatment-naive Chronic Hepatitis B Patients: Long-term Real-world Experience.
KDDW 2017.
대한민국
(2017)
Efficacy and safety of ledipasvir / sofosbuvir therapy in HCV genotype 1 korean patients.
APDW 2017.
중국
(2017)
Changes of liver fibrosis parameters after daclatasvir plus asunaprevir therapy in genotype 1b chronic hepatitis C Korean patients.
APDW 2017.
중국
(2017)
Comparison of Methods Estimate Liver Function in New-ly-Diagnosed Hepatocellular Carcinoma Patients with Ascites.
Liver Week 2017.
대한민국
(2017)
Performance of Fivrosis Markers for Hepatocellular Carci-noma Development in Chronic Hepatitis B Patients under Antiviral Therapy.
Liver Week 2017.
대한민국
